High-mannose N-linked glycans recognized by carbohydrate-binding agents (CBAs) are potential targets for topical microbicides. To better understand the mechanisms by which CBAs inhibit human immunodeficiency virus (HIV)-1 infection at the molecular level, we systematically analysed the contribution of site-specific glycans to the anti-HIV activity of CBAs by site-directed mutagenesis. Our results demonstrate that a single deglycosylation at N295 or N448 in a range of primary and T-cell-line-adapted HIV-1 isolates resulted in marked resistance to griffithsin (GRFT) but maintained the sensitivity to cyanovirin (CV-N), Galanthus nivalis agglutinin (GNA) and a range of neutralizing antibodies. Unlike CV-N and GNA, the interaction between GRFT and gp120 appeared to be dependent on the specific trimeric 'sugar tower' including N295 and N448. This was further strengthened by the results of GRFT-Env binding experiments. Our study identifies GRFT-specific gp120 glycans and may provide information for the design of novel CBA antiviral strategies.
In the absence of a protective vaccine, there is an urgent need to develop topical microbicides to prevent the sexual transmission of human immunodeficiency virus (HIV)-1. gp120 is a highly glycosylated protein, with approximately 24 N-linked carbohydrates accounting for as much as 50 % of its mass. Carbohydrate-binding agents (CBAs), which directly interact with the viral envelope glycans and block viral infection, may represent good microbicide candidates to prevent HIV-1 transmission.
A range of anti-HIV CBAs have been isolated and characterized, including Galanthus nivalis agglutinin (GNA), isolated from snowdrop (Van Damme et al., 1987) , cyanovirin-N (CV-N) from the cyanobacterium Nostoc ellipsosporum (Boyd et al., 1997) , and griffithsin (GRFT) from the red alga Griffithsia sp. (Mori et al., 2005) . Among these, CV-N has been intensively investigated (Bolmstedt et al., 2001; Boyd et al., 1997; Esser et al., 1999) . CV-N binds to high-mannose glycans, in particular a(1, 2)-linked mannose oligomers (Bewley, 2001; Bolmstedt et al., 2001) , and is, so far, the only CBA demonstrating efficacy and safety in macaque-challenge studies (Tsai et al., 2003 (Tsai et al., , 2004 , thus it is a potential topical microbicide candidate (Balzarini, 2005; Shattock & Moore, 2003) . GRFT, the most potent CBA identified to date, also binds to high-mannose glycans on HIV-1 gp120. GRFT has a unique primary amino acid sequence compared with other CBAs (Mori et al., 2005) . GRFT demonstrates antiviral activity against a wide range of HIV-1 isolates and exhibits biocompatibility and extraordinary stability (Emau et al., 2007; O'Keefe et al., 2009) . In addition, GRFT-P, a recombinant GRFT protein produced in tobacco, is non-toxic in a rabbit vaginal irritancy model as well as in human cervical explants (O'Keefe et al., 2009) , making it an excellent candidate for anti-HIV microbicides.
Owing to its high mutation rate, resistant HIV-1 rapidly emerges under persistent drug selection pressure (Balzarini et al., 2006; Hu et al., 2007) . Therefore, it is crucial to predict the molecular basis for resistance to potential topical microbicides. HIV-1 resistance to CV-N, by deletion of multiple high-mannose N-linked glycosylation sites (NLGs), has been well described (Balzarini et al., 2006; Hu et al., 2007) . Similarly, HIV-1 resistance to GRFT is IP: 54.70.40.11
On: Sun, 06 Jan 2019 22:43:49 associated with deletion of high-mannose NLGs from asparagine (N)230 to N448 in the C2-C4 region of gp120 (Alexandre et al., 2010) . However, previous studies were mainly based on CBA-resistant HIV-1 with multiple depletions of high-mannose NLGs or fragment deletions containing non-glycosylation residues (Alexandre et al., 2010; Balzarini et al., 2006; Witvrouw et al., 2005) . The proportional contribution of an individual NLG on gp120 to CBA resistance remains elusive. Moreover, the effect of site-specific deglycosylations has not been addressed systematically.
Given that subtype C HIV-1 is the predominant subtype in sub-Saharan Africa and accounts for more than 50 % of global infections, we chose a subtype C MWS2 env (Hu et al., 2005) cloned from semen to conduct our initial experiments. We introduced a series of third-site substitutions from serine/threonine (S/T) to alanine (A) or T/S in the potential high-mannose NLGs of gp120 (Gallaher et al., 1995; Leonard et al., 1990; Zhu et al., 2000) and examined their role in the anti-HIV activity of CBAs. We first carried out infection assays using Env-pseudotyped viruses to infect TZM-bl cells, as described previously (Hu et al., 2007) . Glycan mutants N262-S264A and N448-T450A showed a sharp reduction in infectivity, demonstrating 25 and~21 % of wild-type (WT) infectivity, respectively; other glycan mutants had infectivities ranging from 61 to 115 % of the WT level (Table 1 and Supplementary Table  S1 , available in JGV Online). We then introduced conservative first-site substitutions from asparagine to glutamine (Q) at NLG sites N262 and N448, respectively. Glycan mutants N262Q and N448Q displayed 31 and 115 % infectivity, respectively, compared with WT (Table 1  and Supplementary Table S1 ). Because infectivity is closely related to the steric configuration of Env, removal of glycans may contribute to the modification of structure and function of HIV-1 Env.
We next tested the sensitivity of MWS2 glycan mutants to GRFT (Intrucept Biomedicine), CV-N (Biosyn) and GNA (Sigma). The majority of glycan mutants were sensitive to GRFT, CV-N and GNA (Table 1, Fig. 1b and Supplementary Table S1 ). Mutants N295-T297A and N448-T450A showed dramatically decreased sensitivities to GRFT. The IC 50 of the two mutants increased~110-fold and~157-fold, respectively. In contrast, mutants N295-T297A and N448-T450A demonstrated similar sensitivities to CV-N and GNA compared with WT Env, while N448-T450A showed marginally enhanced sensitivity to GNA. A similar resistance pattern was seen in U87.CD4.CCR5 cells (data not shown). Another point of interest is that N262-S264A had a remarkably increased sensitivity to GRFT, with an IC 50 ,0.008 nM (Supplementary Table S1 ). To determine whether the resistance of N448-T450A to GRFT was because of the sharp reduction of infectivity or the deletion of the high-mannose NLG at N448, we tested the sensitivity of first-site substituted mutant N448Q to GRFT. N448Q, which showed good infectivity in the pseudotyped-virus infection assay, also clearly displayed enhanced resistance to GRFT, with an IC 50 of 1.824 nM (Supplementary Table S1 ), while the IC 50 of GRFT against WT was 0.012 nM. Taken together, high-mannose NLGs at N295 and N448 may be the optimal binding sites for GRFT, while CV-N and GNA probably bind to additional glycans.
To confirm the observation obtained with MWS2 Env, we carried out experiments using Env proteins from different clades and phenotypes, including: a subtype A 93TH976-17, a subtype BC CH811 (cloned from PBMCs of a Chinese patient) and two subtype B Envs, BaL (macrophage tropic R5) and IIIB (T-cell adapted X4) (Hu et al., 2000) . 93TH976-17 has six high-mannose NLG deletions at N230, N295, N301, N332, N339 and N386. BaL lacks two highmannose NLGs at N230 and N234. CH811 lacks two highmannose NLGs at N295 and N339. MWS2 lacks one glycan at N289 (Fig. 1a) . In particular, the Env proteins of 93TH976-17 and CH811 do not have the NLG at N295; therefore, we introduced N295 into these two Env proteins by site-directed mutagenesis, and named the mutants 93TH976-17-S295N and CH811-E295N, respectively. We conducted Env-pseudotyped infection assays by using TZM-bl cells to test whether these glycan mutants were infection competent. Third-site substitution of serine or threonine with alanine at N448 resulted in sharply reduced infection (Table 1) . Env mutants 93TH976-17-N448-T450A and CH811-N448-T450A almost lost infectivity, while other third-site substitutions at N448 displayed 21-31 % of the infectivity of WT. It is notable that mutants N295-T297A and N448Q had infectivities similar to that of WT. Interestingly, the infectivity of 93TH976-17, which lacks N295, and 93TH976-17-N448Q, with deglycosylations at N295 and N448, was approximately fourfold greater than that of mutants 93TH976-17-S295N and 93TH976-17-S295NN448Q.
To investigate the significance of NLGs at N295 and N448, we retrieved gp160 sequences from the HIV database (http://www.hiv.lanl.gov) and analysed the conservation of these glycosylation sites in gp120 of subtype A, B and C Envs ( Supplementary Fig. S1 , available in JGV Online). N448 is highly conserved, with an amino acid identity .71 %. In comparison,~82 % of subtype B and~56 % of subtype A HIV-1 contain NLG at N295, while onlỹ 16.5 % of subtype C virus are glycosylated at the same site. Subsequent experiments were focused on N295 and N448 Env mutants because the roles of these glycans in infection and in their sensitivities to CBAs and antibodies remain to be clarified.
Previous studies have suggested that GRFT binds to highmannose-type glycans of HIV-1 gp120 (Mori et al., 2005) . Removal of high-mannose NLGs from N230 to N448, including N295, has been suggested to render HIV-1 resistant to GRFT (Alexandre et al., 2010; Hu et al., 2007) . In agreement with this, our results in the current study indicate that high-mannose NLGs at N295 and/or N448 on MWS2 Env may be crucial for the anti-HIV activity of GRFT. We conducted inhibition assays to test the Journal of General Virology 92 50 is given in parentheses. IgG1 b12 recognizes epitopes on gp120 overlapping the CD4 binding region (key residues D185 and P369 change to N185 and L369 in 93TH976-17 and MWS2, respectively); 447-52D recognizes the highly conserved amino acid sequence GPGR of the V3 loop (93TH976-17 and CH811; the sequence is GPGQ in MWS2). 2F5 recognizes gp41 amino acid sequence ELDKWA (the sequence is ALDRWQ in MWS2). 1101 is a IIIB-specific murine mAb. Data shown are representative of at least three independent experiments. ND, Not done. *The lack of an N-linked glycosylation site at N295 was reversed by site-directed mutagenesis and the mutants named 93TH976-17-S295N and CH811-E295N, respectively. DResistance is because of the lack of key amino acids recognized by the antibody. d93TH976-17 and CH811 Env proteins lack the N-linked glycosylation site at N295. §93TH976-17-S295NN448Q and CH811-E295NN448Q were deglycosylated at N448 and the lack of N-linked glycosylation site at N295 was reversed. ||Deglycosylation double mutant with glycan deletion at both N295 and N448.
GRFT specific glycans on HIV gp120 sensitivity of a range of Env proteins to GRFT, CV-N and GNA. Env mutants with single deglycosylation mutation at N295 or N448 of the gp120 proteins of 93TH976-17, IIIB, BaL and CH811 all demonstrated resistance to GRFT (Fig.  1b) . In contrast, all Env glycan mutants, except 93TH976-17 and IIIB-N295-T297A, were sensitive to CV-N and GNA. IIIB-N295-T297A demonstrated increased sensitivity to GNA, in agreement with a previous report by Huskens et al., (2007) .
Mutants with a single deleted glycan at N295 or N448 clearly showed resistance to GRFT. Therefore, doubly deglycosylated mutants were constructed by using N295-deglycosylated Env as a template to deplete the high-mannose NLG at N448. Compared with the singledeglycosylation mutants at N259 or N448, doubly deglycosylated mutants showed enhanced resistance to GRFT (Fig. 1b) . We subsequently performed GRFT-binding experiments. N295-T297A, N448-T450A or N295-T297AN448Q Env-pseudotyped viruses demonstrated markedly less binding activity to GRFT-coated 96-well plates than viruses with WT Env (Fig. 2a) , as determined by ELISA (Hu et al., 2004) . Taken together, our data indicate that high-mannose NLGs at N295 and N448, rather than other high-mannose glycans, are highly likely to be the optimal binding sites for GRFT.
The N-linked glycans act as sugar shields to mask the conserved CD4 binding site and other neutralizing epitopes, playing important roles in immune escape from the host (Kwong et al., 1998; Reitter et al., 1998; Wei et al., 2003; Wyatt et al., 1998) . Depletion of glycans may facilitate the exposure of immunogenic epitopes that are recognized by the immune system. Therefore, we performed experiments to test the sensitivity of Env mutants N295-T297A, N448-T450A or N448Q to human immunoglobulins pooled from 
HIV
+ patients (HIV-IG) and a range of well-characterized mAbs, including CD4-IgG2, b12, 17b, 2G12, 447-52D, 4E10, 2F5 and MAb1101 (ImmunoDiagnostics).
The majority of N295-T297A and N448-T450A, or N448Q Env mutants, except 93TH976-17 and MWS2-N448-T450A, maintained susceptibility to HIV-IG (Table 1) . The neutralization sensitivity of MWS2-N448-T450A increased approximately fourfold compared with that of WT. In addition, 93TH976-17, lacking several NLG sites, displayed decreased sensitivity to HIV-IG compared with 93TH976-17-S295N. Mutants with deglycosylation at N295 showed markedly decreased sensitivity to anticarbohydrate antibody 2G12 (Calarese et al., 2003; Sanders et al., 2002; Scanlan et al., 2002) . However, deletion of glycan at N448 did not affect the susceptibility of HIV-1 to 2G12, with BaL-N448-T450A showing a slightly decreased susceptibility to 2G12. All Env mutants demonstrated a similar level of sensitivity to CD4-IgG2 as to the sensitivity of WT. In addition, the sensitivity of 93TH976-17-S295N to CD4-IgG2 is~15-fold higher than that of 93TH976-17. Furthermore, the majority of Env mutants maintained neutralizing sensitivity to a range of well-characterized mAbs (b12, 17b, 447-52D, 2F5, 4E10 and MAb1101), while IIIB-N295-T297A exhibited decreased susceptibility to 447-52D compared with IIIB (Table 1) . Taken together, our data provide evidence that a single site-specific deglycosylation at N295 or N448 on gp120 renders HIV-1 resistant to GRFT but maintains its sensitivity to most of the tested antibodies.
In conclusion, our results demonstrate that a single deletion of a site-specific high-mannose NLG at N295 or N448, which gather together with N332 to form a trimeric glycan cluster, renders MWS2 Env resistant to GRFT. This was further strengthened by the results demonstrating that deglycosylation at N295 or N448 in a range of HIV-1 Envs, regardless of subtype and tropism, clearly affected the anti-HIV activity of GRFT. Dual deglycosylation at N295 and N448 showed enhanced resistance to GRFT over a single deglycosylation at N295 or N448. Nevertheless, the deglycosylated double mutants could still be inhibited by very high concentrations of GRFT. Given the high selectivity index for GRFT, it is likely that such levels could be safely achieved with a topically applied microbicide. In contrast, the majority of these glycan-deleted Env mutants maintained their sensitivities to CV-N and GNA. Moreover, 93TH976-17 Env, with six high-mannose glycan deletions, including N295, maintained sensitivity to GRFT, suggesting that other NLGs, in addition to N295, are involved in the anti-HIV activity of GRFT. This is strengthened by the observation that, excluding N295 and N448, all other single high-mannose deglycosylations of MWS2 gp120 had little effect on the sensitivity of HIV-1 to GRFT. Also of note is that all Env mutants including N295-T297A and N448-T450A or N448Q were sensitive to CV-N and GNA. Further experiments confirmed that MSW2 N295-T297A, N448-T450A and N295-T297AN448Q had markedly reduced binding activity with GRFT. Together our data imply that the interaction between GRFT and gp120 is determined by the specific location of high-mannose NLGs rather than the number of glycans.
The binding pattern of GRFT on gp120 may be related to its own special structure and the steric configuration of site-specific high-mannose glycans. The primary amino acid sequence of GRFT is quite different from other CBAs (Mori et al., 2005) . GRFT inhibits HIV-1 infection more effectively than CV-N and GNA, probably owing to its having a total of six mannose binding sites per homodimer (Zió łkowska et al., 2006 (Zió łkowska et al., , 2007 , while CV-N has only four binding sites (Bewley, 2001) . We propose a model (Fig.  2b) . Although there are three glycan clusters on gp120 (Balzarini et al., 2006) , it is likely that only glycans at N295, N332 and N448 (cluster II) gather together to form a unique high-mannose 'sugar tower' as an optimal binding site for GRFT. This high-mannose trimer may be more readily recognized by GRFT than by CV-N or GNA. A single deglycosylation in the glycan trimer may result in rearrangement of adjacent glycans and clearly has a deleterious impact on GRFT binding. N262 is very close to the high-mannose glycan trimer and may provide steric hindrance, interfering with the binding of GRFT to the 'sugar tower'. Deglycosylation at N262 probably leads to sufficient exposure of the neighbouring high-mannose trimer for GRFT. This may explain why glycan mutant N262-S264A had sharply enhanced sensitivity to GRFT, whereas mutation at N332 did not affect GRFT sensitivity. It is probable that the glycan at N332 acts as a scaffold to maintain the high-mannose trimer rather than as the direct binding site for GRFT. Most HIV-1 subtype-C Envs which lack high-mannose N295 are sensitive to CBAs (Alexandre et al., 2010; O'Keefe et al., 2009) . In contrast, the highmannose NLG at N448 is highly conserved (.71 % amino acid identity), probably compensating for the binding of GRFT in the absence of N295.
Findings in the current study revealed that a single deglycosylation at N295 or N448 on gp120 rendered HIV-1 resistant to GRFT while maintaining sensitivity to GNA, CV-N and neutralizing antibodies. In addition, deglycosylation of N448 by third-site mutagenesis almost completely abolished infectivity, suggesting its significance in maintaining the function of HIV-1 Env. Our data reveal a unique, novel anti-HIV pattern of GRFT and may have implications for the design of novel CBA antiviral strategies.
